Form 4: Atara Biotherapeutics Director Receives Equity Grant
Statement of Changes in Beneficial Ownership
Director Gregory A. Ciongoli was granted 12,000 restricted stock units by Atara Biotherapeutics, Inc.
Summary
- Director Gregory A. Ciongoli received an award of 12,000 restricted stock units (RSUs) on June 9, 2026.
- The RSUs are scheduled to vest on the earlier of June 9, 2027, or the date of the next annual meeting of stockholders, contingent upon continuous service.
- The reporting person maintains an indirect beneficial interest in 1,209,395 shares held by Adiumentum Capital Fund I LP.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which is neutral in terms of immediate market impact.
Positives
- Alignment of director interests with shareholders through equity-based compensation.
Negatives
- None identified.
Risks
- Vesting is subject to the director's continuous service to the company.
Future Outlook
The RSU grant is subject to standard vesting conditions tied to the director's continued service and the timing of the next annual stockholder meeting.
Industry Context
StockSavvy.ai notes that equity grants to board members are standard corporate governance practices in the biotechnology sector to ensure long-term alignment between leadership and shareholder value.
Comparison to Industry Standards
- The use of RSU grants for director compensation is consistent with standard practices for NASDAQ-listed biotechnology companies.
- The vesting period of approximately one year aligns with typical annual equity refresh cycles for board members.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Power of Attorney | Director Gregory A. Ciongoli appointed Yanina Grant-Huerta and John Chao as attorneys-in-fact for SEC filings. | 06/11/2026 | Administrative update to facilitate timely regulatory compliance. |
Related Party Transactions
- The director is the managing partner of Adiumentum Capital Fund I LP, which holds 1,209,395 shares of the company.
Stakeholder Impact
- Minimal impact on shareholders; reflects standard director compensation.
Next Steps
- Vesting of 12,000 RSUs on June 9, 2027, or the next annual meeting.
Key Dates
| Date | Description |
|---|---|
| 06/09/2026 | Date of RSU grant transaction. |
| 06/11/2026 | Date of Power of Attorney execution and filing signature. |
| 06/09/2027 | Scheduled vesting date for the RSU grant. |
Keywords
Atara Biotherapeutics, ATRA, Form 4, Insider Transaction, Equity Grant, Director Compensation
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.